1.
Mak A. IL-17 Inhibitors and the Risk of Malignancy. Can Dermatol Today [Internet]. 2022 Mar. 1 [cited 2024 Nov. 21];3(1):21–24. Available from: https://canadiandermatologytoday.com/article/view/3-1-mak